Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

NCT02495896 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

61

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma
Metastatic Pancreatic Adenocarcinoma
Non-Resectable Cholangiocarcinoma
Pancreatic Adenocarcinoma
Recurrent Gallbladder Carcinoma
Recurrent Non-Small Cell Lung Carcinoma
Stage III Pancreatic Cancer
Stage IIIA Gallbladder Cancer
Stage IIIA Non-Small Cell Lung Cancer
Stage IIIB Gallbladder Cancer
Stage IIIB Non-Small Cell Lung Cancer
Stage IV Gallbladder Cancer
Stage IV Non-Small Cell Lung Cancer
Stage IV Pancreatic Cancer
Unresectable Gallbladder Carcinoma
Unresectable Pancreatic Cancer

Interventions

DRUG: Cisplatin
DRUG: Docetaxel
DRUG: Gemcitabine Hydrochloride
OTHER: Laboratory Biomarker Analysis
DRUG: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
OTHER: Pharmacological Study
BIOLOGICAL: Recombinant EphB4-HSA Fusion Protein

Sponsor

University of Southern California

Collaborators

[object Object]
[object Object]